Experienced in Appendix Cancer

Dr. Emily N. Prendergast

Gynecologic Oncology | Obstetrics and Gynecology | Oncology
Ihc Health Services Inc
8 Th Ave And C St, 
Salt Lake City, UT 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Experienced in Appendix Cancer
Ihc Health Services Inc
8 Th Ave And C St, 
Salt Lake City, UT 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Emily Prendergast is a Gynecologic Oncologist and an Obstetrics and Gynecologist in Salt Lake City, Utah. Dr. Prendergast is rated as an Experienced provider by MediFind in the treatment of Appendix Cancer. Her top areas of expertise are Ovarian Cancer, Endometrial Cancer, Ovarian Carcinosarcoma, Sertoli-Leydig Cell Tumor, and Hernia Surgery. Dr. Prendergast is currently accepting new patients.

Her clinical research consists of co-authoring 16 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Gynecologic Oncology
Obstetrics and Gynecology
Oncology
Licenses
Obstetrics & Gynecology in MN
Hospital Affiliations
Intermountain Medical Center
Lds Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BridgeSpan
  • EPO
  • HMO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Deseret Mutual Benefit Administrators
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
EMI Health
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Regence
  • EPO
  • PPO
SelectHealth
  • HMO
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

IHC HEALTH SERVICES INC
8 Th Ave And C St, Salt Lake City, UT 84143
Other Locations
IHC HEALTH SERVICES INC
324 E 10th Ave, Suite 200, Salt Lake City, UT 84103
IHC HEALTH SERVICES INC
5063 S Cottonwood St, Suite 160, Murray, UT 84107
IHC HEALTH SERVICES INC
5121 S Cottonwood St, Murray, UT 84107
IHC HEALTH SERVICES INC
5131 S Cottonwood St, Murray, UT 84107

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]
A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]
Enrollment Status: Recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Procedure
Study Phase: Not Applicable
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody-Drug Conjugate (ADC), in Patients With Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody-Drug Conjugate (ADC), in Patients With Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers
Enrollment Status: Completed
Publish Date: August 20, 2025
Intervention Type: Drug
Study Drug: STRO-002
Study Phase: Phase 1
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 13, 2025
Intervention Type: Drug
Study Drugs: Niraparib, Dostarlimab
Study Phase: Phase 3
A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) Alone and In Combination With Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) Alone and In Combination With Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
Enrollment Status: Active_not_recruiting
Publish Date: January 29, 2025
Intervention Type: Drug
Study Drugs: VS-6766, Defactinib
Study Phase: Phase 2
A Phase 2 Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Patients With Platinum-Resistant Ovarian Cancer (MOONSTONE)
A Phase 2 Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Patients With Platinum-Resistant Ovarian Cancer (MOONSTONE)
Enrollment Status: Terminated
Publish Date: September 10, 2022
Intervention Type: Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

16 Total Publications

Erratum: Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201.
Erratum: Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 13, 2025
Similar Doctors
Advanced in Appendix Cancer
Dr. Jonathan R. Whisenant
Oncology
Advanced in Appendix Cancer
Dr. Jonathan R. Whisenant
Oncology

Utah Cancer Specialists - Murray

5131 South Cottonwood Street, Suite L2, 
Murray, UT 
 (8.3 miles away)
801-263-3416
Experience:
27+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jonathan Whisenant is an Oncologist in Murray, Utah. Dr. Whisenant has been practicing medicine for over 27 years and is rated as a Distinguished provider by MediFind in the treatment of Appendix Cancer. His top areas of expertise are Cholangiocarcinoma (Bile Duct Cancer), Gastrointestinal Stromal Tumor, Colorectal Cancer, and Familial Colorectal Cancer. Dr. Whisenant is currently accepting new patients.

Advanced in Appendix Cancer
Dr. Glynn W. Gilcrease
Oncology | Hematology
Advanced in Appendix Cancer
Dr. Glynn W. Gilcrease
Oncology | Hematology

University Of Utah Adult Services

1950 Circle Of Hope Dr, 
Salt Lake City, UT 
 (2.4 miles away)
801-581-8793
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Glynn Gilcrease is an Oncologist and a Hematologist in Salt Lake City, Utah. Dr. Gilcrease is rated as a Distinguished provider by MediFind in the treatment of Appendix Cancer. His top areas of expertise are Familial Colorectal Cancer, Colorectal Cancer, Familial Pancreatic Cancer, Liver Embolization, and Endoscopy. Dr. Gilcrease is currently accepting new patients.

Experienced in Appendix Cancer
Dr. Ignacio Garrido-Laguna
Oncology | Hematology
Experienced in Appendix Cancer
Dr. Ignacio Garrido-Laguna
Oncology | Hematology

University Of Utah Adult Services

1950 Circle Of Hope Dr, 
Salt Lake City, UT 
 (2.4 miles away)
801-581-8793
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Ignacio Garrido-Laguna is an Oncologist and a Hematologist in Salt Lake City, Utah. Dr. Garrido-Laguna is rated as a Distinguished provider by MediFind in the treatment of Appendix Cancer. His top areas of expertise are Pancreatic Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Pancreatoblastoma, and Pancreatectomy. Dr. Garrido-Laguna is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Prendergast's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 27 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile